Fulcrum Therapeutics, Inc. (FULC)
Last updated: 2026-10-21 21:20:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Fulcrum Therapeutics, Inc. (FULC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.72, with a market capitalization of $282.61M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.83 to $15.74. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$282.61M | |
$3.72 | |
$33.10 | |
$2.25 | |
$3.72 | |
842.80K | |
1.52M | |
-- | |
$15.74 | |
$2.83 | |
-- | |
-- |
Fulcrum Therapeutics, Inc. (FULC) After-Hours Stock Price
Fulcrum Therapeutics, Inc. (FULC) is trading at $3.71 in after-hours trading as of 2026-10-21 19:59:56, down 0.27% ($0.01) from the regular-session close of $3.72.
After-hours trading shows how investors are pricing FULC after the regular session closes. The current after-hours price is near the regular-session close, indicating cautious after-hours sentiment.
Fulcrum Therapeutics, Inc. (FULC) 7-Day Stock Price Change
Over the past seven days, Fulcrum Therapeutics, Inc. (FULC) moved from $3.75 to $3.72, representing a decline of 0.93% ($0.04).
The stock traded between $3.64 and $3.77 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.33 million shares, down versus the previous seven-day period, indicating lower trading activity.
FULC 52-Week Price Position
Position in Range: 6.9%
FULC is currently trading at $3.72, placing it 6.9% of the way from its 52-week low of $2.83 to its 52-week high of $15.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Fulcrum Therapeutics, Inc. (FULC)?
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Fulcrum Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Fulcrum Therapeutics, Inc. (FULC) Stock on MEXC
Eligible investors can buy real shares of Fulcrum Therapeutics, Inc. (FULC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Fulcrum Therapeutics, Inc. (FULC) stock price today?
2.Is FULC stock going up or down today?
3.What is FULC pre-market price?
4.What is FULC after-hours price?
5.Is FULC stock trading now?
6.Where does FULC sit relative to its 52-week high and low?
7.What sector is Fulcrum Therapeutics, Inc. in?
8.What is Fulcrum Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is FULC valued in terms of P/E ratio and EPS?
10.Does Fulcrum Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
FULC Stock Calculator
Estimate the value between FULC shares and USD.
FULC Shares to USD
1.00 FULC shares = 3.715 USD
Calculations are estimates based on the latest available price and are for reference only.


